Some haemorheological factors in patients with arteriosclerosis obliterans after treatment of trental.
Erythrocytes deformability, plasma cAMP, 6-keto-PGF1 alpha, TXB2 levels and fibrinolytic activity in patients suffering from arteriosclerosis obliterans before and after Trental were studied. Trental improved the deformability of red cells and resulted in an enhancement of diminished cAMP level in plasma and increased the fibrinolytic activity. The improvement of deformability observed after Trental could depend upon the influence of a higher cAMP level in plasma on the erythrocyte membrane. The increase of cAMP level seems to be the result of the inhibiting effect of Trental on phosphodiesterase and of higher fibrinolytic activity.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000368:Aged; D001162:Arteriosclerosis Obliterans / Q000097:blood / Q000188:drug therapy*; D000242:Cyclic AMP / Q000097:blood; D004907:Erythrocyte Deformability / Q000187:drug effects*; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000627:therapeutic use*; D012212:Rheology; D013805:Theobromine / Q000031:analogs & derivatives*; D013929:Thromboxane B2 / Q000097:blood
D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D000242:Cyclic AMP; D013805:Theobromine; D010431:Pentoxifylline